Researchers are rapidly examining retatrutide, a promising treatment from Eli Lilly, as a significant breakthrough in physique loss . Unlike many earlier approaches, retatrutide is a twin-action agonist targeting simultaneously GLP-1 and GIP, chemicals that influence appetite and blood glucose co